#1393

Hu Kaijun

China 64 years old Self-Made

Overview

Source of Wealth
Pharmaceuticals
Industry
Healthcare
Residence
Beijing

Assets

  • Grand Pharmaceutical Group
    1,796,400,000 shares @ -
    -
    512-HK
  • Huadong Medicine Co. Ltd.
    646,112,000 shares @ -
    -
    000963-CN
  • Huadong Medicine Co. Ltd.
    0 shares @ -
    -
    000963-CN
  • Lianyungang Ideal Group
    200,139,000 shares @ -
    -
    000626-CN

Biography

Hu Kaijun is chairman and CEO of China Grand Enterprises, an investment company with interests in healthcare, real estate, agriculture and financial services.

China Grand is the parent of three publicly-traded companies: Grand Pharmaceutical, Huadong Medicine (a wholesaler) and Grand Industrial Holding (a trading business).

Grand Pharmaceutical agreed to buy 87.5% of U.S.-based vascular drug maker BlackSwan Vascular for $37.5 million in 2023.

Hu also wholly owns Beijing Yuanda Huachuang Investment, where he also serves as chairman and CEO.

Hu's wealth is derived primarily from Grand China's stakes in Huadong Medicine and Grand Pharmaceutical.